Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18859 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von A Marouf und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high‐risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV‐naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV‐exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France.
- Service Hématologie, AP-HP, Hôpital Cochin, Paris, France.
- Groupe Hospitalier privé Ambroise Paré-Hartmann, Département Recherche Innovation, Neuilly-Sur-Seine, France.
- IDESP, INSERM, PreMEdical INRIA, Univ Montpellier, CHU Montpellier, Montpellier, France.
- Paris Est University, Créteil, France.
- Service Hémopathies Lymphoïdes, AP-HP, Hôpital Henri Mondor, Créteil, France.
ORCID-Profile: A Marouf, D Sibon, C Herbaux, C Rossi, H Ghesquieres, B Deau
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Marouf, A., Molinari, N., Sibon, D., Cottereau, A. S., Kanoun, S., Antoine, C., Debureaux, P. E., Cavalieri, D., Fornecker, L. M., Casasnovas, R. O., Herbaux, C., Amorim, S., Rossi, C., Bouscary, D., Brice, P., Ghesquieres, H., Tamburini, J., & Deau, B. (2023). Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. British Journal of Haematology. https://doi.org/10.1111/bjh.18859
Vancouver
Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, et al. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. British Journal of Haematology. 2023. doi:10.1111/bjh.18859
BibTeX
@article{Marouf2023,
author = {Marouf, A and Molinari, N and Sibon, D and Cottereau, A S and Kanoun, S and Antoine, C and Debureaux, P E and Cavalieri, D and Fornecker, L M and Casasnovas, R O and Herbaux, C and Amorim, S and Rossi, C and Bouscary, D and Brice, P and Ghesquieres, H and Tamburini, J and Deau, B},
title = {Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18859}
}
EUVIMED